The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD)

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Liu, Qing ^a,c   Bengmark, Stig ^b   Qu, Shen ^a  

^a TONGJI UNIVERSITY   (China)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FAT;

ANIMAL; FATTY LIVER; HUMAN; LIVER; METABOLIC SYNDROME X; METABOLISM; REVIEW;

ANIMALS; FATS; FATTY LIVER; HUMANS; LIVER; METABOLIC SYNDROME X;

EID: 77951539837     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-42     Document Type: Review

References (101)

1. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. Farrell GC, Chitturi S, Lau GK, Sollano JD, Asia-Pacific Working Party on NAFLD, J Gastroenterol Hepatol 2007 22 775 7 10.1111/j.1440-1746.2007.05002.x 17565629
2. Recent concepts in non-alcoholic fattyliver disease. Adams LA, Angulo P, Diabet Med 2005 22 1129 1133 10.1111/j.1464-5491.2005.01748.x 16108837
3. Non alcoholic fatty liver disease: a clinical approach and review. Raman M, Allard J, Can J Gastroenterol 2006 20 345 9 16691301
4. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications. Fan JG, J Dig Dis 2008 9 63 7 10.1111/j.1751-2980.2008.00323.x 18419637
5. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Boppidi H, Daram SR, Postgrad Med 2008 120 01 7 10.3810/pgm.2008.07.1800 18654060
6. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K, N Engl J Med 2006 355 2297 307 10.1056/NEJMoa060326 17135584
7. New insights into the pathophysiology of nonalcoholic fatty liver disease. Chávez-Tapia NN, Uribe M, Ponciano-Rodríguez G, Medina-Santillán R, Méndez-Sánchez N, Ann Hepatol 2009 8 9 S17 19381119
8. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Abrams GA, Kunde SS, Lazenby AJ, Clements RH, Hepatology 2004 40 475 83 10.1002/hep.20323 15368453
9. Are non-invasive tests accurate enough to predict hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD)? Chavez-Tapia NC, Tiribelli C, Gut 2008 57 1351 3 10.1136/gut.2008.154435 18791116
10. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Brunt EM, Semin Diagn Pathol 2005 22 330 338 10.1053/j.semdp.2006.04. 002 16939061
11. Pathology of nonalcoholic fatty liver disease. Yeh MM, Brunt EM, Am J Clin Pathol 2007 128 837 847 10.1309/RTPM1PY6YGBL2G2R 17951208
12. Nonalcoholic fatty liverdisease/nonalcoholic steatohepatitis: Histological diagnostic criteria and scoring systems. Tiniakos DG, European Journal of Gastroenterology & Hepatology 2009 00
13. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ, J Clin Invest 2005 115 1343 1351 15864352
14. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Abdul-Ghani MA, Tripathy D, DeFronzo RA, Diabetes Care 2006 29 1130 9 10.2337/dc05-2179 16644654
15. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T, Impaired Glucose Tolerance for Atherosclerosis and Diabetes study, Diabetes Care 2003 26 868 74 10.2337/diacare.26.3.868 12610051
16. The role of the lipogenic pathway in the development of hepatic steatosis. Postic C, Girard J, Diabetes & Metabolism 2008 34 643 648
17. Central insulin action regulates peripheral glucose and fat metabolism in mice. Koch L, Wunderlich FT, Seibler J, Könner AC, Hampel B, Irlenbusch Brabant G, Kahn CR, Schwenk F, Brüning JC, J Clin Invest 2008 118 2132 47 18451994
18. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Blüher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, Kahn CR, Dev Cell 2002 3 25 38 10.1016/S1534-5807(02)00199-5 12110165
19. Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation. Reddy JK, Rao MS, Am J Physiol Gastrointest Liver Physiol 2006 290 852 G858 10.1152/ajpgi.00521.2005 16603729
20. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA, Arterioscler Thromb Vasc Biol 2004 24 644 9 10.1161/01.ATV.0000116217.57583.6e 14715643
21. Fatty liver and insulin resistance: not always linked. Schonfeld G, Yue P, Lin X, Chen Z, Trans Am Clin Climatol Assoc 2008 119 217 23 18596860
22. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI, Biol Chem 2004 279 32345 53 10.1074/jbc.M313478200
23. Fatty liver and non-alcoholic steatohepatitis. Saito T, Misawa K, Kawata S1, Intern Med 2007 46 101 3 10.2169/internalmedicine.46.1784 17220609
24. Insulin degradation: progress and potential. Duckworth WC, Bennett RG, Hamel FG, Endocr Rev 1998 19 608 624 10.1210/er.19.5.608 9793760
25. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Meier JJ, Veldhuis JD, Butler PC, Diabetes 2005 54 1649 56 10.2337/diabetes.54.6.1649 15919785
26. Extraction of insulin by liver. Field JB, Annu Rev Med 1973 24 309 314 10.1146/annurev.me.24.020173.001521 4575861
27. Differences in the hepatic and renal extraction of insulin and glucagon in the dog: evidence for saturability of insulin metabolism. Polonsky K, Jaspan J, Emmanouel D, et al. Acta Endocrinol 1983 102 420 427 6338678
28. Effect of intraduodenal glucose administration on hepatic extraction of insulin in the anesthetized dog. Kaden M, Harding P, Field JB, J Clin Invest 1973 52 2016 2028 10.1172/JCI107386 4719675
29. Estimation of the secretion rate of insulin from the urinary excretion rate of C-peptide: study in obese and diabetic subjects. Meistas MT, Rendell M, Margolis S, Kowarski AA, Diabetes 1982 31 449 453 10.2337/diabetes.31.5.449 6759260
30. Hepatic removal of insulin in normal man:dose response to endogenous insulin secretion. Eaton RP, Allen RC, Schade DS, J Clin Endocrinol Metab 1983 56 1294 1300 10.1210/jcem-56-6-1294 6341392
31. Insulinproduction rate following glucose ingestion estimated by splanchnic C-peptide output in normal man. Waldhäusl W, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P, Diabetologia 1979 17 221 227 10.1007/BF01235858 499682
32. C-peptide as a measure of the secretion and hepatic extraction of insulin: pitfalls and limitations. Polonsky KS, Rubenstein AH, Diabetes 1984 33 486 494 10.2337/diabetes.33.5.486 6373457
33. Effect of liver fat on insulin clearance. Kotronen A, Vehkavaara S, Seppälä-Lindroos A, Bergholm R, Yki-Järvinen H, Am J Physiol Endocrinol Metab 2007 293 1709 15 10.1152/ajpendo.00444.2007 17895288
34. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H, Gastroenterology 2008 135 122 30 10.1053/j.gastro.2008.03.021 18474251
35. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A, NASH Clinical Research Network, J Hepatol 2008 48 829 834 10.1016/j.jhep.2008.01.016 18321606
36. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. Postic C, Girard J, J Clin Invest 2008 118 829 38 10.1172/JCI34275 18317565
37. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Choi SS, Diehl AM, Curr Opin Lipidol 2008 19 295 300 10.1097/MOL.0b013e3282ff5e55 18460922
38. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM, Hepatology 2007 45 1366 74 10.1002/hep.21655 17476695
39. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. Li ZZ, Berk M, McIntyre TM, Feldstein AE, J Biol Chem 2009 284 5637 44 10.1074/jbc.M807616200 19119140
40. Biochemical and physiological function of stearoyl-CoA desaturase. Paton CM, Ntambi JM, Am J Physiol Endocrinol Metab 2009 297 28 37 10.1152/ajpendo. 90897.2008 19066317
41. Hepatic stearoyl-coa desaturase (scd)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Kotronen A, Seppänen-Laakso T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepää AL, Oresic M, Yki-Järvinen H, Diabetes 2009 58 203 8 10.2337/db08-1074 18952834
42. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. Shimano H, Yahagi N, Amemiya-Kudo M, Hasty AH, Osuga J, Tamura Y, Shionoiri F, Iizuka Y, Ohashi K, Harada K, Gotoda T, Ishibashi S, Yamada N, J Biol Chem 1999 274 35832 9 10.1074/jbc.274.50.35832 10585467
43. Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis. Brown JM, Chung S, Sawyer JK, Degirolamo C, Alger HM, Nguyen T, Zhu X, Duong MN, Brown AL, Lord C, Shah R, Davis MA, Kelley K, Wilson MD, Madenspacher J, Fessler MB, Parks JS, Rudel LL, Arterioscler Thromb Vasc Biol 2010 30 24 30 10.1161/ATVBAHA.109.198036 19834103
44. Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis. Brown JM, Chung S, Sawyer JK, Degirolamo C, Alger HM, Nguyen T, Zhu X, Duong MN, Wibley AL, Shah R, Davis MA, Kelley K, Wilson MD, Kent C, Parks JS, Rudel LL, Circulation 2008 118 1467 75 10.1161/CIRCULATIONAHA.108.793182 18794388
45. Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Flowers MT, Ntambi JM, Curr Opin Lipidol 2008 19 248 56 10.1097/MOL. 0b013e3282f9b54d 18460915
46. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A, NASH Clinical Research Network, J Hepatol 2008 48 829 834 10.1016/j.jhep.2008.01.016 18321606
47. Hepatic steatosis relationship among histological, radiological and biochemical assessments. Vuppalanchi R, Cummings OW, Saxena R, Ulbright TM, Martis N, Jones DR, Bansal N, Chalasani N, J Clin Gastroenterol 2007 41 206 210 10.1097/01.mcg.0000225515.28536.3a 17245221
48. Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. Rinella ME, McCarthy R, Thakrar K, Finn JP, Rao SM, Koffron AJ, Abecassis M, Blei AT, Liver Transplantation 2003 9 851 856 10.1053/jlts.2003.50153 12884199
49. Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey. Zhang B, Menzin J, Friedman M, Korn JR, Burge RT, Curr Med Res Opin 2008 24 2711 7 10.1185/03007990802363198 18701005
50. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK, Am J Gastroenterol 2009 104 861 7 10.1038/ajg.2009.67 19293782
51. Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease. Mills SJ, Harrison SA, Curr Gastroenterol Rep 2005 7 32 6 10.1007/s11894-005-0063-4 15701296
52. Natural history of nonalcoholic steatohepatitis. Liou I, Kowdley KV, J Clin Gastroenterol 2006 40 Suppl 1 11 6 16540761
53. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Farrell GC, Larter CZ, Hepatology 2006 43 99 S112 10.1002/hep.20973 16447287
54. Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Rubinstein E, Lavine JE, Schwimmer JB, Semin Liver Dis 2008 28 380 5 10.1055/s-0028-1091982 18956294
55. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K, J Gastroenterol Hepatol 2009 24 248 54 10.1111/j.1440-1746.2008.05640.x 19032450
56. Pathogenesis of non-alcoholic fatty liver disease. Dowman JK, Tomlinson JW, Newsome PN, QJM 2010 103 71 83 10.1093/qjmed/hcp158 19914930
57. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Maher JJ, Leon P, Ryan JC, Hepatology 2008 48 670 8 10.1002/hep.22399 18666225
58. Nonalcoholic Steatosis and Steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Diehl AM, Am J Physiol Gastrointest Liver Physiol 2002 282 1 G5 11751151
59. Innate immunity in the liver. Li Z, Diehl AM, Curr Opin Gastroenterol 2003 19 565 71 10.1097/00001574-200311000-00009 15703606
60. Role of inflammation in nonalcoholic steatohepatitis. Choi S, Diehl AM, Curr Opin Gastroenterol 2005 21 702 7 10.1097/01.mog.0000182863.96421.47 16220049
61. Cellular mechanism of insulin resistance: potential links with inflammation. Perseghin G, Petersen K, Shulman GI, Int J Obes Relat Metab Disord 2003 27 Suppl 3 6 S11 10.1038/sj.ijo.0802491 14704736
62. The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors. Lee JY, Hwang DH, Mol Cell 2006 21 174 185
63. Prevention of fat-induced insulin resistance by salicylate. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI, J Clin Invest 2001 108 437 446 11489937
64. Neutralization of tumor necrosis factor-alpha reverses insulin resistance in skeletal muscle but not adipose tissue. Borst SE, Lee Y, Conover CF, Shek EW, Bagby GJ, Am J Physiol Endocrinol Metab 2004 287 934 8 10.1152/ajpendo. 00054.2004 15213061
65. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes. Lorenzo M, Fernández-Veledo S, Vila-Bedmar R, Garcia-Guerra L, De Alvaro C, Nieto-Vazquez I, J Anim Sci 2008 86 14 Suppl 94 104 17940160
66. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, Nagaoka S, Matsumoto T, Takii Y, Kusumoto K, Nakamura M, Komori A, Yano K, Yatsuhashi H, Eguchi K, Ishibashi H, Liver Int 2006 26 39 45 10.1111/j.1478-3231.2005.01191.x 16420507
67. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Bahcecioglu IH, Yalniz M, Ataseven H, Ilhan N, Ozercan IH, Seckin D, Sahin K, Hepatogastroenterology 2005 52 1549 53 16201116
68. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B, Sonnenborn U, Eckert J, Schumann RR, Wiedenmann B, Dignass AU, Sturm A, Infect Immun 2006 74 4075 4082 10.1128/IAI.01449-05 16790781
69. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK, Am J Gastroenterol 2004 99 1946 52 10.1111/j.1572-0241.2004.40220.x 15447754
70. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Adams LA, Zein CO, Angulo P, Lindor KD, Am J Gastroenterol 2004 99 2365 8 10.1111/j.1572-0241.2004.40064.x 15571584
71. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R, Diabetes 1996 45 881 5 10.2337/diabetes.45.7. 881 8666137
72. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Hotamisligil GS, Diabetes 2005 54 Suppl 2 73 S78 10.2337/diabetes.54.suppl-2.S73 16306344
73. Cellular mechanism of insulin resistance: potential links with inflammation. Perseghin G, Petersen K, Shulman GI, Int J Obes Relat Metab Disord 2003 27 Suppl 3 6 S11 10.1038/sj.ijo.0802491 14704736
74. Inflammation and insulin resistance. Shoelson SE, Lee J, Goldfine AB, J Clin Invest 2006 116 1793 1801 10.1172/JCI29069 16823477
75. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. Malhi H, Bronk SF, Werneburg NW, Gores GJ, J Biol Chem 2006 281 12093 12101 10.1074/jbc.M510660200 16505490
76. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ, Gastroenterology 2003 125 437 443 10.1016/S0016-5085(03)00907-7 12891546
77. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ, Hepatology 2006 43 163 172 10.1002/hep.20999 16374858
78. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Gao Z, Zhang X, Zuberi A, Hwang D, Quon MJ, Lefevre M, Ye J, Mol Endocrinol 2004 18 2024 2034 10.1210/me.2003-0383 15143153
79. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI, J Biol Chem 2004 279 32345 32353 10.1074/jbc.M313478200 15166226
80. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI, J Clin Invest 2007 117 739 745 10.1172/JCI30400 17318260
81. Local and systemic insulin resistance resulting from hepatic activation of IKKbeta and NF-kappaB. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE, Nat Med 2005 11 183 190 10.1038/nm1166 15685173
82. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Carter-Kent C, Zein NN, Feldstein AE, Am J Gastroenterol 2008 103 1036 42 10.1111/j.1572-0241.2007.01709.x 18177455
83. siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A, Diabetes 2008 57 2066 73 10.2337/db07-0763 18443205
84. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. Bouzakri K, Zierath JR, J Biol Chem 2007 282 7783 9 10.1074/jbc.M608602200 17227768
85. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Song MJ, Kim KH, Yoon JM, Kim JB, Biochem Biophys Res Commun 2006 4;346 3 739 45 10.1016/j.bbrc.2006.05.170
86. TLR4 links innate immunity and fatty acid-induced insulin resistance. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS, J Clin 2006 116 11 3015 25
87. Innate immunity. Medzhitov R, Janeway C Jr, N Engl J Med 2000 343 338 344 10.1056/NEJM200008033430506 10922424
88. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, Araújo EP, Vassallo J, Curi R, Velloso LA, Saad MJ, Diabetes 2007 56 8 1986 98 10.2337/db06-1595 17519423
89. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B, Sonnenborn U, Eckert J, Schumann RR, Wiedenmann B, Dignass AU, Sturm A, Infect Immun 2006 74 4075 4082 10.1128/IAI.01449-05 16790781
90. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E, Gastroenterology 2004 126 520 528 10.1053/j.gastro.2003.11.019 14762789
91. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM, Hepatology 2003 37 343 350 10.1053/jhep.2003.50048 12540784
92. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C, J Clin Gastroenterol 2005 39 540 543 10.1097/01.mcg.0000165671.25272.0f 15942443
93. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Tolllike receptor 2 dimerized with Toll-like receptor 6 or 1. Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, Lee WH, Fitzgerald KA, Hwang DH, J Biol Chem 2004 279 16971 16979 10.1074/jbc.M312990200 14966134
94. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, De Minicis S, Nobili L, Salzano R, Omenetti A, Pacetti D, Sigmund S, Benedetti A, Casini A, Am J Pathol 2006 169 846 860 10.2353/ajpath.2006.050953 16936261
95. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Accili D, Arden KC, Cell 2004 117 421 426 10.1016/S0092-8674(04) 00452-0 15137936
96. FoxO proteins in insulin action and metabolism. Barthel A, Schmoll D, Unterman TG, Trends Endocrinol Metab 2005 16 183 189 10.1016/j.tem.2005.03.010 15860415
97. FoxO1 integrates insulin signaling to VLDL production. Kamagate A, Dong HH, Cell Cycle 2008 7 3162 3170 18927507
98. Foxo1 Mediates Insulin Action on ApoC-III and Triglyceride Metabolism. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH, J Clin Invest 2004 114 1493 1503 15546000
99. Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism. Qu S, Altomonte J, Perdomo G, He J, Fan Y, Kamagate A, Meseck M, Dong HH, Endocrinology 2006 147 5641 5652 10.1210/en.2006-0541 16997836
100. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH, J Clin Invest 2008 118 2347 2364 18497885
101. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY, N Engl J Med 2007 356 1517 1526 10.1056/NEJMoa065213 17429083